Proxy completion of EQ-5D in patients with dementia

被引:72
作者
Bryan, S
Hardyman, W
Bentham, P
Buckley, A
Laight, A
机构
[1] Univ Birmingham, Hlth Econ Facil, Hlth Serv Management Ctr, Birmingham, W Midlands, England
[2] Social Care Inst Excellence, London, England
[3] Queen Elizabeth Psychiat Hosp, Mental Hlth Serv Older Adults, Birmingham B15 2QZ, W Midlands, England
[4] Pk View Clin, Language Unit, Birmingham, W Midlands, England
关键词
construct validity; dementia; proxy; quality of life;
D O I
10.1007/s11136-004-1920-6
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
There are measurement difficulties associated with the assessment of health-related quality of life (HRQL) in older people with dementia. The use of proxies is a commonly employed approach to overcome such problems. The research reported in this paper sought to identify, specifically for the EuroQol EQ-5D HRQL instrument, whether construct validity is greater for 'family caregivers' or 'clinicians' as two alternative sources of proxy information for patients with a diagnosis of dementia. This involved the exploration of the strength of the associations between clinical measures of illness severity and EQ-5D data. The data appear to reveal a pattern suggesting that the viewpoint of the proxy (i.e., clinician or family caregiver) is important. The findings suggest that the data provided by clinicians (when compared to data from carers) had higher construct validity for the more observable dimensions of the EQ-5D instrument (i.e., 'mobility' and 'self-care'). Conversely, the data from family carers had higher construct validity for the less observable dimensions (i.e., 'usual activities' and 'anxiety/depression'). Previous research on proxy provision of HRQL data has tended to focus on trying to identify a single proxy. The results of this study suggest that using carefully matched sets of measures and assessment perspectives may produce more valid EQ-5D health state descriptions.
引用
收藏
页码:107 / 118
页数:12
相关论文
共 36 条
[1]  
Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease. Technology Appraisal Guidance No. 19, (2001)
[2]  
Brazier J., Deverill M., Green C., Harper R., Booth A., A review of the use of health status measures in economic evaluation, Health Technol Assess, 3, 9, (1999)
[3]  
Zimmerman S.I., Magaziner J., Methodological issues in measuring the functional status of cognitively impaired nursing home residents: The use of proxies and performance based measures, Alzheimer Disease Assoc Disorders, 8, 1 SUPPL., (1994)
[4]  
Selai C., Trimble M.R., Assessing quality of life in dementia, Aging Mental Health, 3, 2, pp. 101-111, (1999)
[5]  
Magaziner J., Use of proxies to measure health and functional outcomes in effectiveness research in persons with Alzheimer disease and related disorders, Alzheimer Dis Associ Disorders, 6 SUPPL., pp. 168-174, (1997)
[6]  
Rabin R., De Charro F., EQ-5D: A measure of health status from the EuroQol Group, Ann Med, 33, pp. 337-343, (2001)
[7]  
Coucill W., Bryan S., Bentham P., Buckley A., Laight A., EQ-5D as a measure of health-related quality of life in patients with cognitive impairment: An investigation of inter-rater reliability, 16th Plenary Meeting of the EuroQol Group, pp. 169-188, (1999)
[8]  
Coucill W., Bryan S., Bentham P., Buckley A., Laight A., EQ-5D in dementia: An investigation of inter-rater agreement, Med Care, 39, 8, pp. 760-771, (2001)
[9]  
Devellis R.F., Scale Development - Theory and Applications, (1991)
[10]  
Bucks R.S., Ashworth D., Wilcock G.K., Siegfried K., Assessment of daily living in dementia: Development of the Bristol Activities of Daily Living Scale, Age Ageing, 25, pp. 113-120, (1996)